{
  "first_published_at": "2011-07-06", 
  "original_url": "http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON123125", 
  "title": "Octagam intravenous immunoglobulin 5% and 10%: lifting of licence suspensions", 
  "tags": "{\"parsed_therapeutic\": [\"immunology-vaccination\"], \"Audience:\": [\"Secondary care\", \"Primary care\"], \"Therapeutic area:\": [\"Immunology and vaccination\"]}", 
  "_document_number": 145, 
  "label": null, 
  "icon": null, 
  "therapeutic_area": [
    "immunology-vaccination"
  ], 
  "raw_html": "<div id=\"dsuArticleContent\">\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\t<h1><a name=\"maincontent\" id=\"maincontent\"></a>Octagam intravenous immunoglobulin 5% and 10%: lifting of licence suspensions</h1>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<span class=\"ref\">Article date: July 2011</span> \r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element21)-->\r\n\t\t\t\t\t\t\t\t<!--After an in-depth review of available safety and quality data, the suspension of the licences (marketing authorisations) for Octagam (intravenous human normal immunoglobulin 5% and 10%) has now been lifted.-->\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element21)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element22)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element22)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element13)-->\r\n\t\t\t\t\t\t\t\t<!--<p>After an in-depth review of available safety and quality data, the suspension of the licences (marketing authorisations) for Octagam (intravenous human normal immunoglobulin 5% and 10%) has now been lifted. This follows advice from the European Medicines Agency&rsquo;s Committee for Medicinal Products for Human Use (CHMP).</p><p>In September 2010, CHMP recommended suspension of the licences for Octagam after an increased frequency of the known risk of thromboembolic adverse events (eg, stroke, myocardial infarction, and pulmonary embolism; see <a href=\"http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON096802\">Drug Safety Update October 2010</a>).</p><p>The increased risk of these events was related to a manufacturing defect, which led to increased levels of thrombogenic substances in the finished Octagam product. A number of measures have now been implemented, including an improved manufacturing process and a thrombogenicity testing before batches of Octagam are released to the market. CHMP was reassured that future production of Octagam would meet the required quality standards and therefore recommended lifting the suspension.</p><p>As with all medicines, we will continue to closely monitor the safety of Octagam in the UK.</p><div class=\"dull_highlight\">\r\n\t\t\t<p><strong>Advice for healthcare professionals:</strong></p>\r\n\t\t\t<ul>\r\n\t\t\t\t<li>After implementation of new safeguards and improvements to the manufacturing process for Octagam, the benefits of this product are considered to outweigh the risks.</li>\r\n\t\t\t\t<li>As with all medicines, any suspected adverse reactions should be reported at <a href=\"http://www.yellowcard.gov.uk\">www.yellowcard.gov.uk</a>.</li>\r\n\t\t\t</ul></div><p><strong>Further information:</strong></p><p>European Medicines Agency: <a href=\"http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/public_health_alerts/2011/04/human_pha_detail_000026.jsp&murl=menus/medicines/medicines.jsp&mid=WC0b01ac058001d126\" target=\"_blank\">European safety review for Octagam</a></p><p>&nbsp;</p><p><em>Article citation: Drug Safety Update July 2011, vol 4 issue 12: S1.</em></p>-->\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element13)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!-- SS_BEGIN_SNIPPET(fragment7,1)-->\r\n\t\t\t\t\t\t\t\t<!-- call include to dynamically insert alt attributes into image tags within a wysiwyg element -->\r\n<!-- get a reference to the wysiwyg content -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n\t<p>After an in-depth review of available safety and quality data, the suspension of the licences (marketing authorisations) for Octagam (intravenous human normal immunoglobulin 5% and 10%) has now been lifted. This follows advice from the European Medicines Agency&#8217;s Committee for Medicinal Products for Human Use (CHMP).</p><p>In September 2010, CHMP recommended suspension of the licences for Octagam after an increased frequency of the known risk of thromboembolic adverse events (eg, stroke, myocardial infarction, and pulmonary embolism; see <a href=\"http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON096802\">Drug Safety Update October 2010</a>).</p><p>The increased risk of these events was related to a manufacturing defect, which led to increased levels of thrombogenic substances in the finished Octagam product. A number of measures have now been implemented, including an improved manufacturing process and a thrombogenicity testing before batches of Octagam are released to the market. CHMP was reassured that future production of Octagam would meet the required quality standards and therefore recommended lifting the suspension.</p><p>As with all medicines, we will continue to closely monitor the safety of Octagam in the UK.</p><div class=\"dull_highlight\">\r\n\t\t\t<p><strong>Advice for healthcare professionals:</strong></p>\r\n\t\t\t<ul>\r\n\t\t\t\t<li>After implementation of new safeguards and improvements to the manufacturing process for Octagam, the benefits of this product are considered to outweigh the risks.</li>\r\n\t\t\t\t<li>As with all medicines, any suspected adverse reactions should be reported at <a href=\"http://www.yellowcard.gov.uk\">www.yellowcard.gov.uk</a>.</li>\r\n\t\t\t</ul></div><p><strong>Further information:</strong></p><p>European Medicines Agency: <a href=\"http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/public_health_alerts/2011/04/human_pha_detail_000026.jsp&amp;murl=menus/medicines/medicines.jsp&amp;mid=WC0b01ac058001d126\" target=\"_blank\">European safety review for Octagam</a></p><p>&#160;</p><p><em>Article citation: Drug Safety Update July 2011, vol 4 issue 12: S1.</em></p>\r\n\t\t\t\r\n\t\t\t\t\t\t\t\t<!-- SS_END_SNIPPET(fragment7,1)-->\r\n\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t", 
  "date_of_article": "2011-07-01", 
  "date_last_modified": "2011-07-11", 
  "_assets": [], 
  "_item_id": 145, 
  "summary": "", 
  "body": "Article date: July 2011\n\nAfter an in-depth review of available safety and quality data, the suspension of the licences (marketing authorisations) for Octagam (intravenous human normal immunoglobulin 5% and 10%) has now been lifted. This follows advice from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP).\n\nIn September 2010, CHMP recommended suspension of the licences for Octagam after an increased frequency of the known risk of thromboembolic adverse events (eg, stroke, myocardial infarction, and pulmonary embolism; see [Drug Safety Update October 2010](http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON096802)).\n\nThe increased risk of these events was related to a manufacturing defect, which led to increased levels of thrombogenic substances in the finished Octagam product. A number of measures have now been implemented, including an improved manufacturing process and a thrombogenicity testing before batches of Octagam are released to the market. CHMP was reassured that future production of Octagam would meet the required quality standards and therefore recommended lifting the suspension.\n\nAs with all medicines, we will continue to closely monitor the safety of Octagam in the UK.\n\nAdvice for healthcare professionals:  \n  \n  * After implementation of new safeguards and improvements to the manufacturing process for Octagam, the benefits of this product are considered to outweigh the risks.  \n  * As with all medicines, any suspected adverse reactions should be reported at [www.yellowcard.gov.uk](http://www.yellowcard.gov.uk).  \n  \nFurther information:\n\nEuropean Medicines Agency: [European safety review for Octagam](http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/public_health_alerts/2011/04/human_pha_detail_000026.jsp&murl=menus/medicines/medicines.jsp&mid=WC0b01ac058001d126)\n\n \n\nArticle citation: Drug Safety Update July 2011, vol 4 issue 12: S1.\n"
}